The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants ...

A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

Sanofi (SNY)'s share was trading at $51.06 ... by deep public-sector distribution—generated €2.25 billion, and MenQuadfi, a meningitis vaccine, posted 50.5% growth. Despite some expected ...

Meningitis remains a significant health problem, affecting 2.5 million people annually and causing death and disability despite the availability of vaccines such as Sanofi’s MenQuadfi that ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

We have just scratched the surface as to how we embrace these disruptive technologies to achieve our ambition of transforming the practice of medicine”, Paul Hudson, CEO of Sanofi. In under two ...

Sanofi SAN-0.90%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...